These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 14682412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program.
    Albers M, Schermer T, van den Boom G, Akkermans R, van Schayck C, van Herwaarden C, van Weel C.
    Chest; 2004 Dec; 126(6):1815-24. PubMed ID: 15596679
    [Abstract] [Full Text] [Related]

  • 4. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec; 10():2431-8. PubMed ID: 26648706
    [Abstract] [Full Text] [Related]

  • 5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.
    Ann Intern Med; 2009 Oct 20; 151(8):517-27. PubMed ID: 19841453
    [Abstract] [Full Text] [Related]

  • 10. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 20; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 11. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
    Thompson WH, Carvalho P, Souza JP, Charan NB.
    Lung; 2002 Jun 20; 180(4):191-201. PubMed ID: 12391509
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
    Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK.
    BMJ; 2000 May 13; 320(7245):1297-303. PubMed ID: 10807619
    [Abstract] [Full Text] [Related]

  • 14. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 15. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun 15; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial.
    Ayres JG, Price MJ, Efthimiou J.
    Respir Med; 2003 Mar 15; 97(3):212-20. PubMed ID: 12645827
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS.
    Chest; 2007 Dec 15; 132(6):1756-63. PubMed ID: 17951625
    [Abstract] [Full Text] [Related]

  • 18. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.
    Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB.
    Thorax; 2002 Aug 15; 57(8):694-700. PubMed ID: 12149529
    [Abstract] [Full Text] [Related]

  • 19. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ, Postma DS, Klooster K, Lapperre TS, Vonk JM, Sont JK, Kerstjens HAM, Snoeck-Stroband JB, Hiemstra PS, Sterk PJ, GLUCOLD Study GroupDepartment of Pulmonology, LUMC, Leiden, The Netherlands..
    Chest; 2015 Aug 15; 148(2):389-396. PubMed ID: 25836351
    [Abstract] [Full Text] [Related]

  • 20. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.